| First Author | Blanchet MR | Year | 2007 |
| Journal | Blood | Volume | 110 |
| Issue | 6 | Pages | 2005-12 |
| PubMed ID | 17557898 | Mgi Jnum | J:146399 |
| Mgi Id | MGI:3837521 | Doi | 10.1182/blood-2006-12-062448 |
| Citation | Blanchet MR, et al. (2007) CD34 facilitates the development of allergic asthma. Blood 110(6):2005-12 |
| abstractText | Asthma is a pulmonary inflammatory disease dependent on eosinophil and mast cell infiltration into the lung. CD34 is a sialomucin expressed by both of these cell types, and we have used CD34(-/-) mice and a standard mouse model of asthma to evaluate the importance of CD34 expression on disease development. In comparison with wild-type (wt) mice, CD34(-/-) mice exhibited a dramatic reduction in all hallmarks of allergic asthma, including lowered airway inflammatory cell infiltration, airway hyperresponsiveness, and mast-cell recruitment. Bone marrow transplantation experiments confirmed that these defects are due to CD34 expression by bone marrow-derived cells. This was not, however, due to an inability to respond to antigen as, on a per cell basis, wt and CD34(-/-) inflammatory cells exhibit identical responses in cytokine production. We found a striking reduction in mobility of CD34(-/-) eosinophils in vitro, the major component of inflammatory infiltrates, which was consistent with proposed models for CD34 as an inhibitor of cell-cell adhesion. In summary, our data suggest that CD34 enhances mast-cell and eosinophil invasiveness and that its expression by these cells is a prerequisite for development of allergic asthma. |
